In the second segment of this roundtable series, the panel discusses the importance of safe sampling in biomarker testing. The efficacy of zongertinib was evaluated in Beamion LUNG-1, an open-label, multicenter, multi-cohort trial. In the seventh part of this roundtable series, the panel discusses surgical preparations and considerations. In the sixth segment of this roundtable series, the discusses how multidisciplinary teams monitor and manage AEs. In the fifth segment of the roundtable series, experts discuss advances in adjuvant, neoadjuvant and perioperative treatment. In the fourth segment of this roundtable discussion, the panel shares navigation strategies for patients with NSCLC. In the third part of this roundtable discussion, experts share insights on the decision-making process surrounding treatment Dr. Osarogiagbon discussed the impact of the lung cancer screening program on diagnosis rates across the Mississippi Delta. In the second segment of this roundtable discussion, experts discuss considerations surrounding biospies and biomarkers. Dr. Jänne reflects on the importance of World Lung Cancer Day, which is marked on August 1 annually. In the first segment of this multidisciplinary roundtable, experts discuss progress and challenges in lung cancer screening. In the final segment of the roundtable discussion, the panel reflects on pressing unanswered questions in lung cancer. In the fourth segment of this roundtable discussion, the panel weighs in on the most pressing unmet needs in NSCLC. In the third segment of this roundtable discussion, the panel discusses considerations for community oncologists. In the second segment of this roundtable discussion, the panel discusses the molecular testing landscape in NSCLC. FLAURA2 Principal Investigator, Pasi A. Jänne, MD, PhD, discusses the final overall survival analysis from the phase 3 ... In the first segment of this roundtable discussion, the panel explores the rising incidence of young-onset lung cancer. Osimertinib plus chemotherapy showed a “statistically significant and clinically meaningful improvement" in overall ... In the second segment of this interview, Feldman discussed the importance of patient advocacy in clinical trial research. Jorge Nieva, MD, explains new findings showing how steroids impact survival in patients undergoing ICI therapy.